The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...
If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.
AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.
AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...
A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss ...
Alison Dziarmaga, Vice President and U.S. Breast Cancer Franchise Head at AstraZeneca, ...
AstraZeneca's drug Truqap in combination with two other medications secured approval for the treatment of a form of advanced prostate cancer by the Food and Drug Administration. Approval was based on ...
The Manila Times on MSN
Encouraging trial results for AstraZeneca's new weight-loss pill
PARIS — A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to ...
The Lung Cancer Research Foundation (LCRF), in collaboration with AstraZeneca, today announced that two research awards ...
AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...
AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of its ...
AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results